Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

876 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Influence of pre-existing invasive aspergillosis on allo-HSCT outcome: a retrospective EBMT analysis by the Infectious Diseases and Acute Leukemia Working Parties.
Penack O, Tridello G, Hoek J, Socié G, Blaise D, Passweg J, Chevallier P, Craddock C, Milpied N, Veelken H, Maertens J, Ljungman P, Cornelissen J, Thiebaut-Bertrand A, Lioure B, Michallet M, Iacobelli S, Nagler A, Mohty M, Cesaro S. Penack O, et al. Among authors: socie g. Bone Marrow Transplant. 2016 Mar;51(3):418-23. doi: 10.1038/bmt.2015.237. Epub 2015 Oct 26. Bone Marrow Transplant. 2016. PMID: 26501769
Long-term outcome after allogeneic hematopoietic stem cell transplantation for advanced stage acute myeloblastic leukemia: a retrospective study of 379 patients reported to the Société Française de Greffe de Moelle (SFGM).
Michallet M, Thomas X, Vernant JP, Kuentz M, Socié G, Espérou-Bourdeau H, Milpied N, Blaise D, Rio B, Reiffers J, Jouet JP, Cahn JY, Bourhis JH, Lioure B, Leporrier M, Sotto JJ, Souillet G, Sutton L, Bordigoni P, Dreyfus F, Tilly H, Gratecos N, Attal M, Leprise PY, Déméocq F, Michel G, Buzyn A, Delmas-Marsalet B, Bernaudin F, Ifrah N, Sadoun A, Guyotat D, Cavazzana-Cavo M, Caillot D, De Revel T, Vannier JP, Baruchel A, Fegueux N, Tanguy ML, Thiébaut A, Belhabri A, Archimbaud E. Michallet M, et al. Among authors: socie g. Bone Marrow Transplant. 2000 Dec;26(11):1157-63. doi: 10.1038/sj.bmt.1702690. Bone Marrow Transplant. 2000. PMID: 11149725
Recent improvement in outcome of unrelated donor transplantation for aplastic anemia.
Viollier R, Socié G, Tichelli A, Bacigalupo A, Korthof ET, Marsh J, Cornish J, Ljungman P, Oneto R, Békássy AN, Fuehrer M, Maury S, Schrezenmeier H, van Lint MT, Wojcik D, Locasciulli A, Passweg JR. Viollier R, et al. Among authors: socie g. Bone Marrow Transplant. 2008 Jan;41(1):45-50. doi: 10.1038/sj.bmt.1705894. Epub 2007 Nov 5. Bone Marrow Transplant. 2008. PMID: 17982502
Outcome after allogeneic transplantation for adult acute myeloid leukemia patients exhibiting isolated or associated trisomy 8 chromosomal abnormality: a survey on behalf of the ALWP of the EBMT.
Chevallier P, Labopin M, Nagler A, Ljungman P, Verdonck LF, Volin L, Zander AR, Finke J, Socie G, Cordonnier C, Harousseau JL, Mohty M, Rocha V; Acute Leukemia Working Party of the EBMT. Chevallier P, et al. Among authors: socie g. Bone Marrow Transplant. 2009 Nov;44(9):589-94. doi: 10.1038/bmt.2009.68. Epub 2009 Apr 6. Bone Marrow Transplant. 2009. PMID: 19349953
Impact of cytogenetics risk on outcome after reduced intensity conditioning allo-SCT from an HLA-identical sibling for patients with AML in first CR: a report from the acute leukemia working party of EBMT.
Chevallier P, Labopin M, Milpied N, Cornelissen JJ, Blaise D, Petersen E, Sandstedt A, Goker H, Socie G, Rocha V, Mohty M; ALWP of EBMT. Chevallier P, et al. Among authors: socie g. Bone Marrow Transplant. 2012 Nov;47(11):1442-7. doi: 10.1038/bmt.2012.55. Epub 2012 Apr 16. Bone Marrow Transplant. 2012. PMID: 22504932
Prophylaxis and treatment of GVHD: EBMT-ELN working group recommendations for a standardized practice.
Ruutu T, Gratwohl A, de Witte T, Afanasyev B, Apperley J, Bacigalupo A, Dazzi F, Dreger P, Duarte R, Finke J, Garderet L, Greinix H, Holler E, Kröger N, Lawitschka A, Mohty M, Nagler A, Passweg J, Ringdén O, Socié G, Sierra J, Sureda A, Wiktor-Jedrzejczak W, Madrigal A, Niederwieser D. Ruutu T, et al. Among authors: socie g. Bone Marrow Transplant. 2014 Feb;49(2):168-73. doi: 10.1038/bmt.2013.107. Epub 2013 Jul 29. Bone Marrow Transplant. 2014. PMID: 23892326
Outcomes of adults with active or progressive hematological malignancies at the time of allo-SCT: a survey from the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC).
Chevallier P, Labopin M, Milpied N, Bilger K, Socié G, Yakoub-Agha I, Michallet M, Bulabois CE, Maury S, Beguin Y, Bay JO, Blaise D, Maillard N, Guillerm G, Daguindeau E, Raus N, Mohty M. Chevallier P, et al. Among authors: socie g. Bone Marrow Transplant. 2014 Mar;49(3):361-5. doi: 10.1038/bmt.2013.186. Epub 2013 Dec 2. Bone Marrow Transplant. 2014. PMID: 24292522
Impact of in vivo T-cell depletion on outcome of AML patients in first CR given peripheral blood stem cells and reduced-intensity conditioning allo-SCT from a HLA-identical sibling donor: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
Baron F, Labopin M, Blaise D, Lopez-Corral L, Vigouroux S, Craddock C, Attal M, Jindra P, Goker H, Socié G, Chevallier P, Browne P, Sandstedt A, Duarte RF, Nagler A, Mohty M. Baron F, et al. Among authors: socie g. Bone Marrow Transplant. 2014 Mar;49(3):389-96. doi: 10.1038/bmt.2013.204. Epub 2014 Jan 13. Bone Marrow Transplant. 2014. PMID: 24419525 Free article.
Allogeneic hematopoietic SCT for adults AML using i.v. BU in the conditioning regimen: outcomes and risk factors for the occurrence of hepatic sinusoidal obstructive syndrome.
Nagler A, Labopin M, Berger R, Bunjes D, Campos A, Socié G, Kröger N, Goker H, Yakoub-Agha I, Shimoni A, Mohty M, Rocha V. Nagler A, et al. Among authors: socie g. Bone Marrow Transplant. 2014 May;49(5):628-33. doi: 10.1038/bmt.2014.7. Epub 2014 Feb 17. Bone Marrow Transplant. 2014. PMID: 24535127
Comparing i.v. BU dose intensity between two regimens (FB2 vs FB4) for allogeneic HCT for AML in CR1: a report from the Acute Leukemia Working Party of EBMT.
Kharfan-Dabaja MA, Labopin M, Bazarbachi A, Hamladji RM, Blaise D, Socié G, Lioure B, Bermudez A, Lopez-Corral L, Or R, Arcese W, Fegueux N, Nagler A, Mohty M. Kharfan-Dabaja MA, et al. Among authors: socie g. Bone Marrow Transplant. 2014 Sep;49(9):1170-5. doi: 10.1038/bmt.2014.133. Epub 2014 Jun 30. Bone Marrow Transplant. 2014. PMID: 24978140
876 results